CriticalSulfonylureas×Imidazole antifungal
Updated · Methodology
Mechanism
The liver is the main site of gliclazide metabolism (gliclazide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The miconazole oral gel SmPC lists gliclazide, like other sulfonylureas, among the substrates of the enzyme CYP2C9, which miconazole inhibits (miconazole oral gel SmPC, AEMPS). According to the gliclazide SmPC, systemic miconazole and miconazole oral gel increase the glucose-lowering effect of gliclazide (AEMPS). Patients hold the gel in the mouth and then swallow it, so miconazole reaches the blood. After a 60 mg dose, plasma levels peak at 31–49 ng/mL after about 2 hours, and the half-life is 20–25 hours (miconazole oral gel SmPC, AEMPS). Less than 1% of a cream dose is absorbed (miconazole cream SmPC, AEMPS). Each Spanish vaginal ovule contains 100 mg of miconazole with 300 mg of metronidazole. Their SmPC gives data for 1200 mg miconazole ovules: peak plasma levels more than 100 times lower than after oral or intravenous use (vaginal ovule SmPC, AEMPS). The US label of miconazole buccal tablets does not rule out an interaction with oral antidiabetic drugs, although little miconazole reaches the blood after them (US Food and Drug Administration, FDA).
Symptoms
Systemic miconazole and miconazole oral gel increase the glucose-lowering effect of gliclazide, with possible symptoms of hypoglycaemia or even coma (gliclazide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Hypoglycaemia shows as headache, intense hunger, nausea, vomiting, tiredness, sleep disturbance, nervousness, aggression, poor concentration, confusion, visual and speech disturbances, tremor and dizziness. Severe cases cause seizures and loss of consciousness that may progress to coma and death (gliclazide SmPC, AEMPS). The adrenaline response to low blood sugar causes sweating, clammy skin, anxiety, tachycardia, high blood pressure, palpitations, angina and arrhythmias (gliclazide SmPC, AEMPS). Symptoms usually resolve after sugar intake, but with sulfonylureas hypoglycaemia may recur even after initially effective measures (gliclazide SmPC, AEMPS).
Management
The combination is contraindicated: the gliclazide summary of product characteristics (SmPC) lists systemic miconazole and miconazole oral gel among its contraindications (gliclazide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The gel is held in the mouth and then swallowed, so miconazole reaches the blood (miconazole oral gel SmPC, AEMPS). The gel SmPC itself is less strict. For sulfonylureas, gliclazide included, it recommends close blood glucose monitoring and considering a lower sulfonylurea dose. If the gel and gliclazide have nevertheless been combined, measure blood glucose often and decide whether to lower the gliclazide dose (miconazole oral gel SmPC, AEMPS). The gliclazide contraindication covers systemic miconazole and the oral gel and does not mention cream or vaginal ovules. Their SmPCs ask for caution with oral antidiabetic drugs, whose effects and adverse effects may increase (miconazole cream and vaginal ovule SmPCs, AEMPS). Explain to the patient and family the risk of hypoglycaemia, its symptoms and its treatment (gliclazide SmPC, AEMPS). Treat mild hypoglycaemia without loss of consciousness or neurological signs with carbohydrates, not artificial sweeteners, and review the dose and diet (gliclazide SmPC, AEMPS). Severe hypoglycaemia with coma, seizures or other neurological signs is a medical emergency that needs immediate hospital admission. If hypoglycaemic coma is diagnosed or suspected, give a rapid intravenous injection of 50 mL of 20–30% glucose. Then start a continuous 10% glucose infusion to keep blood glucose above 1 g/L, and monitor closely (gliclazide SmPC, AEMPS). Dialysis does not help, because gliclazide is strongly bound to plasma proteins (gliclazide SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Blasgina óvulos vaginales (nº registro 50441), sección 4.5 (2026)– AEMPS, CIMA, nº registro 50441 (Blasgina óvulos vaginales, Almirall), revisión 09/2026, secciones 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Miconazol crema (nº registro 50271), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 50271 (Daktarin 20 mg/g crema), revisión 06/2026, secciones 4.4, 4.5 y 5.2 (en el HTML de CIMA siguen al apartado 4.3, sin ancla propia)
- FDA: ORAVIG (miconazole) buccal tablets prescribing information (2026)– FDA, DailyMed setid dc2427ff-e566-4b48-b289-9e51c011250a, Galt Pharmaceuticals, revisión 01/2026 (versión 3), secciones 7.1, 7.2 y 12.3
- AEMPS: Ficha técnica: Gliclazida, Diamicron 60 mg (nº registro 71738), sección 4.3 (2020)– AEMPS, CIMA, nº registro 71738 (Diamicron 60 mg comprimidos de liberación modificada, Les Laboratoires Servier), revisión 03/2020 (texto revisado 02/2020), secciones 4.3, 4.4, 4.5, 4.8 y 4.9; el mismo texto sobre miconazol en Diamicron 30 mg (nº registro 63644)
- AEMPS: Ficha técnica: Daktarin 20 mg/g gel oral, miconazol (nº registro 55962), sección 4.5 (2026)– AEMPS, CIMA, nº registro 55962 (Daktarin 20 mg/g gel oral, JNTL Consumer Health), revisión 06/2026 (texto revisado 08/2025), secciones 4.2, 4.4, 4.5 y 5.2